JP2019527697A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019527697A5 JP2019527697A5 JP2019505193A JP2019505193A JP2019527697A5 JP 2019527697 A5 JP2019527697 A5 JP 2019527697A5 JP 2019505193 A JP2019505193 A JP 2019505193A JP 2019505193 A JP2019505193 A JP 2019505193A JP 2019527697 A5 JP2019527697 A5 JP 2019527697A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cancer
- composition according
- inhibitor
- pi3k
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662370642P | 2016-08-03 | 2016-08-03 | |
| US62/370,642 | 2016-08-03 | ||
| PCT/US2017/045390 WO2018027084A2 (en) | 2016-08-03 | 2017-08-03 | Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019527697A JP2019527697A (ja) | 2019-10-03 |
| JP2019527697A5 true JP2019527697A5 (https=) | 2020-09-10 |
| JP7187035B2 JP7187035B2 (ja) | 2022-12-12 |
Family
ID=61073805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019505193A Active JP7187035B2 (ja) | 2016-08-03 | 2017-08-03 | 癌を治療するためのグルカゴン受容体アンタゴニストとｐｉ３ｋ経路阻害剤との組み合わせ |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11319376B2 (https=) |
| EP (1) | EP3493847A4 (https=) |
| JP (1) | JP7187035B2 (https=) |
| CN (1) | CN109789210A (https=) |
| AU (1) | AU2017305502B2 (https=) |
| CA (1) | CA3036273A1 (https=) |
| MX (1) | MX2019001467A (https=) |
| WO (1) | WO2018027084A2 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3239447A1 (en) | 2016-01-11 | 2017-07-20 | Syndevrx, Inc. | Treatment for tumors driven by metabolic dysfunction |
| CA3102279A1 (en) | 2018-06-01 | 2019-12-05 | Cornell University | Combination therapy for pi3k-associated disease or disorder |
| JP2022512826A (ja) * | 2018-10-26 | 2022-02-07 | シンデブルックス，インコーポレイティド | ＭｅｔＡＰ２阻害剤のバイオマーカーとその応用 |
| US10653690B1 (en) * | 2019-07-09 | 2020-05-19 | Orexo Ab | Pharmaceutical composition for nasal delivery |
| US20230011916A1 (en) * | 2019-11-21 | 2023-01-12 | Beigene, Ltd. | Methods of cancer treatment using anti-ox40 antibodies in combination with pi3 kinase delta inhibitors |
| CN114958771B (zh) * | 2022-06-27 | 2023-12-05 | 广东康盾创新产业集团股份公司 | 一种ipsc-car-nk细胞的制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CL2007002668A1 (es) * | 2006-09-20 | 2008-05-09 | Amgen Inc | Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2. |
| AU2010247397B2 (en) * | 2009-05-15 | 2012-07-12 | Novartis Ag | Combination of a phosphoinositide 3-kinase inhibitor and an antidiabetic compound |
| BR112013027448A2 (pt) * | 2011-04-28 | 2020-09-01 | Sloan-Kettering Institute For Cancer Research | terapia de combinação com hsp90 |
| WO2015189698A2 (en) * | 2014-06-08 | 2015-12-17 | Beijing Cosci-Remd Bio Med Tech Company Ltd | Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodies |
-
2017
- 2017-08-03 JP JP2019505193A patent/JP7187035B2/ja active Active
- 2017-08-03 MX MX2019001467A patent/MX2019001467A/es unknown
- 2017-08-03 WO PCT/US2017/045390 patent/WO2018027084A2/en not_active Ceased
- 2017-08-03 EP EP17837728.9A patent/EP3493847A4/en not_active Withdrawn
- 2017-08-03 US US16/322,964 patent/US11319376B2/en active Active
- 2017-08-03 CN CN201780061812.9A patent/CN109789210A/zh active Pending
- 2017-08-03 AU AU2017305502A patent/AU2017305502B2/en not_active Expired - Fee Related
- 2017-08-03 CA CA3036273A patent/CA3036273A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019527697A5 (https=) | ||
| JP7579056B2 (ja) | がんのための治療方法及び診断方法 | |
| CN109196121B (zh) | 用于癌症的治疗和诊断方法 | |
| CN113195000A (zh) | 抗体-药物缀合物和激酶抑制剂的组合 | |
| TW201904995A (zh) | IL-1β 結合抗體之用途 | |
| JP2024028805A (ja) | がん処置のための坑ｉｌ－８抗体及び坑ｐｄ－１抗体を用いる組合せ治療 | |
| CN101688229A (zh) | 使用egfr抗体和src抑制剂的治疗方法和相关制剂 | |
| US20230088070A1 (en) | Use of il-1beta binding antibodies | |
| JP2022527373A5 (https=) | ||
| US20220056123A1 (en) | Use of il-1beta binding antibodies | |
| AU2024404811A1 (en) | Anti-cancer combination therapy | |
| CN116406288A (zh) | 使用PD-1拮抗剂、HIF-2α抑制剂、以及乐伐替尼或其药学上可接受的盐的组合，用于治疗癌症或冯-希佩尔-林道病的方法 | |
| WO2020128637A1 (en) | Use of il-1 binding antibodies in the treatment of a msi-h cancer | |
| CN104762371B (zh) | 用于预测或监控c-Met抑制剂效力的生物标志物 | |
| KR102926992B1 (ko) | Tctp에 특이적으로 결합하는 항체 및 이의 용도 | |
| US20260034134A1 (en) | Treatment of cancer with metastases in the central nervous system | |
| JP2022517087A (ja) | 癌の治療のためのｔｉｍ－３抗体および他のチェックポイント阻害剤との組み合わせ | |
| KR102650186B1 (ko) | Api5 단백질에 특이적으로 결합하는 항체 | |
| JP2015503568A (ja) | トラスツズマブに不応性の乳癌の治療方法 | |
| WO2024039925A1 (en) | Combination treatment methods for cancer with tp53 mutation | |
| HK40069361A (en) | Therapeutic and diagnostic methods for cancer | |
| EA052828B1 (ru) | Комбинация конъюгата антитела-лекарственного средства и ингибитора киназы | |
| HK40002960A (en) | Therapeutic and diagnostic methods for cancer | |
| HK40002960B (zh) | 用於癌症的治疗和诊断方法 | |
| NZ614427B2 (en) | Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers |